We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+37.81%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$4.66B
AUM Growth
+$539M
Cap. Flow
-$225M
Cap. Flow %
-4.83%
Top 10 Hldgs %
41.2%
Holding
160
New
26
Increased
26
Reduced
23
Closed
30

Top Buys

Rank Stock Value
1
SEER icon
Seer Inc
SEER
+$372M
2
KRON
Kronos Bio
KRON
+$41.3M
3
SQZ
SQZ Biotechnologies Company
SQZ
+$41M
4
Z icon
Zillow
Z
+$38.7M
5
CCXI
ChemoCentryx, Inc.
CCXI
+$37.2M

Top Sells

Rank Stock Value
1
BNTX icon
BioNTech
BNTX
+$71.8M
2
BABA icon
Alibaba
BABA
+$62.5M
3
MRNA icon
Moderna
MRNA
+$25.3M
4
STNE icon
StoneCo
STNE
+$21.2M
5
SRRK icon
Scholar Rock
SRRK
+$14.3M

Sector Composition

Rank Sector Weight
1 Healthcare 77.21%
2 Consumer Discretionary 9.12%
3 Technology 2.01%
4 Communication Services 1.85%
5 Real Estate 1.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SQZ
26
DELISTED
SQZ Biotechnologies Company
SQZ
$46.6M 1%
+1,606,308
New +$41M
BABA icon
27
CALL
Alibaba
BABA
$279B
$46.5M 1%
+200,000
New +$55.5M
BABA icon
28
Alibaba
BABA
$279B
$46.5M 1%
200,000
-225,000
-53% -$62.5M
TPTX
29
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$42.6M 0.92%
350,000
+25,000
+8% +$2.74M
PRAX icon
30
Praxis Precision Medicines
PRAX
$8.27B
$41.3M 0.89%
+50,000
New +$29.2M
CCXI
31
DELISTED
ChemoCentryx, Inc.
CCXI
$40.2M 0.86%
+650,000
New +$37.2M
KRON
32
DELISTED
Kronos Bio
KRON
$39.4M 0.85%
+1,317,954
New +$41.3M
CERE
33
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$37.8M 0.81%
+2,282,100
New +$29.6M
ITOS
34
DELISTED
iTeos Therapeutics
ITOS
$37M 0.79%
1,094,047
– –
FHTX icon
35
Foghorn Therapeutics
FHTX
$288M
$34.9M 0.75%
+1,720,720
New +$33M
SAGE
36
DELISTED
Sage Therapeutics
SAGE
$34.6M 0.74%
400,000
+177,700
+80% +$13.1M
NBP
37
NovaBridge Biosciences American Depositary Shares
NBP
$190M
$34.2M 0.73%
725,000
– –
DNLI icon
38
Denali Therapeutics
DNLI
$3.82B
$33.5M 0.72%
400,000
– –
SWTX
39
DELISTED
SpringWorks Therapeutics
SWTX
$32.6M 0.7%
450,000
+165,000
+58% +$10.6M
MRSN
40
DELISTED
Mersana Therapeutics
MRSN
$31.9M 0.69%
48,000
+8,000
+20% +$4.45M
TRIL
41
DELISTED
Trillium Therapeutics Inc.
TRIL
$30.9M 0.66%
2,100,000
+600,000
+40% +$8.65M
RUBY
42
DELISTED
Rubius Therapeutics, Inc
RUBY
$28.7M 0.62%
3,778,913
– –
DCPH
43
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$28.5M 0.61%
500,000
-100,000
-17% -$5.93M
TSHA icon
44
Taysha Gene Therapies
TSHA
$1.65B
$27.6M 0.59%
1,040,882
-100,000
-9% -$2.15M
ADVM
45
DELISTED
Adverum Biotechnologies
ADVM
$27.1M 0.58%
250,000
+70,000
+39% +$8.66M
REPL icon
46
Replimune Group
REPL
$447M
$26.7M 0.57%
700,000
– –
ALBO
47
DELISTED
Albireo Pharma Inc
ALBO
$26.3M 0.56%
700,000
-151,405
-18% -$5.51M
ALNY icon
48
CALL
Alnylam Pharmaceuticals
ALNY
$38.3B
$26M 0.56%
+200,000
New +$26.7M
ALXO icon
49
ALX Oncology
ALXO
$264M
$25.9M 0.56%
300,000
+200,000
+200% +$12M
QURE icon
50
uniQure
QURE
$2.87B
$25.3M 0.54%
700,000
-50,000
-7% -$2.11M
1
2
3 4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q4 2020 Portfolio in Review

As of Q4 2020, Artal Group held 160 positions worth $4.66B, up 13% from $4.12B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Artal Group withdrew a net $225M in Q4 2020, closing 30 positions and reducing 23 holdings. Its most notable exit was StoneCo, an estimated $21.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, up from 57% a quarter earlier, followed by Consumer Discretionary and Technology.

Against the trend, Artal Group opened a new position in Seer Inc worth $328M.

  • Artal Group's largest Q4 2020 buy was Seer Inc: 5,840,911 shares worth $328M.
  • Artal Group added most to Zillow in Q4 2020, an estimated $38.7M increase.
  • Artal Group's biggest Q4 2020 reduction was BioNTech, cutting an estimated $71.8M.
  • Artal Group fully exited StoneCo in Q4 2020, selling an estimated $21.2M.
  • Artal Group's ten largest holdings make up 41% of its $4.66B portfolio in Q4 2020.
  • Artal Group opened 26 new positions and closed 30 in Q4 2020.
  • Artal Group's portfolio value rose 13% quarter-over-quarter to $4.66B.

Based on Artal Group's 13F filing for Q4 2020, filed 11 Feb 2021.